Arena Pharmaceuticals Inc (ARNA) Quote

Looks like you posted on 5 stocks and right on only 1, while the others were terrible picks.....Wonder why you just vanished?

what is going to happen to the options we own?

if they put Jim Bowie on the case--- New Orleans would 'shiver'

Arena may hit 100 soon.

WAS THINKING OF GETTING MORE pfiser---]

not now

was a good way of shaking out the shorts

It will! This joint venture is going to be big in my opinion.

Funny thing is I'm not happy. I bought 95 dollar calls on the dip at open and it's not going in that direction lol

Congratulations to everyone! I had been accumulating for over 10 years. Great news!

Congratulations

lol

Makes sense for people to take profit at the open. But a great buying opportunity for others considering its being bought for 100 per share

Glad I bought 10,000 shares last month. :)

ARNA...$97...Plus on Pfizer buyout News...Should give some nice trades today...imo...we shall see...No position at this moment...:partying_face:

The answer is quite simple really..................

Seeking support to get $$ from clueless suckers, and pursue it for what? I don't believe any of this BS!

Clown!

Going to be interesting never the less. I bet many doctors have finally said enough and have been vocal to the FDA whereas before they have mostly tucked tail to keep their profession.

No PM at this time. All depends on fair treatment or not. Onward Thru The Fog my friend! t2monroe at that place where the old man panning for gold exclaims.....!!!

over 8 years ago. Still true. Way to go FDA Dudes. May you be rewarded in this life as well as the afterlife

Powerhouse company! $$$$

Institutions now own 90% of the shares!

Power here. Great company! $$$

I have no idea what is in the gazillion dollar "stimulus" package, but I wonder if it is possible that companies like Arena will get a piece of the action.

I liked ARNA. I really did. I liked ARNA as a buyout target... but there's no way that is gonna happen in this covid environment.

So then I liked ARNA a little less, given the overall state of the economy.

And then it occurred to me that (even though Amit hasn't admitted it yet) - covid is gonna push out our PH III E results so far he's gonna have to do another dilution. Just my opinion-- but it was not even a remote possibility when i really liked this company.

And then... outta nowhere ... Amit wants to double the outstanding share count? WTF is that all about?

I'm out. Not gonna look back. Maybe ARNA will play out OK, but at this point there are much lower-risk plays. And it's obvious Amit is all about making sure his corp staff gets rich (on the stock holders' backs). Nuh uh. Seen that enough. Good luck y'all.... this one is goin to the crapper if his plan to double the share count succeeds.!!

cheers

coop

Guggenheim Securities Mar31 2020 Target to $95

https://www.benzinga.com/news/20/03/15704228/guggenheim-securities-initiates-coverage-on-arena-pharmaceuticals-with-buy-rating-announces-price-ta

Other analyst targets

Firm Analyst Price Target
J.P.Morgan Jessica Fye $58
Bank of America Jason Gerberry $56
Berenberg Patrick Trucchio $60
Citi Investment Research Joel Beatty $71
Credit Suisse Martin Auster $77
Needham & Company Alan Carr $70
RBC Kennen MacKay $83
Wells Fargo Jim Birchenough $60
Leerink Partners Joseph Schwartz $73
Cantor Fitzgerald Alethia Young $62
JMP Securities Jason Butler $79

ARNA to Present at 19th Annual Needham Virtual Healthcare Conference

https://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-19th-annual-needham-virtual-healthcare-conference-on-april-14-301038849.html

Etrasimod Controlled-Release: Analyst upgrades coming soon?

https://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-positive-topline-data-for-new-development-program---etrasimod-controlled-release-cr-301033578.html

does your post in any way relate to my supposition that XXbeagle is this biggest whiner ever registered to any stock msgboard?

$ARNA Arena Pharmaceuticals Reverse split. The split for ARNA took place on June 19, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of ARNA owned pre-split, the shareholder now owned 1 share.

Hey not for nothin -- but that guy Beagle over on Investor Village is the biggest whiner I think I've ever seen on a msg board. He's probably 13 yrs old - just my guess. Whiner. Total fkin whiner. I don't have an account over there that I can post on - but dang -- just wanted to drop a hint -- that XXLegalBeagal person is a dang whiner!!!

News: $ARNA Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10

SAN DIEGO , April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019...

In case you are interested https://marketwirenews.com/news-releases/arena-pharmaceuticals-to-present-at-the-18th-annual-needham-healthcare-conference-on-april-10-7939784.html

Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation

SAN DIEGO, March 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14th Congress of European Crohn's and Colitis Organisation (ECCO).

"The new data presented from the Phase 2 trial of etrasimod demonstrate that both mucosal healing and histological remission were seen in patients with moderate to severe ulcerative colitis following just 12 weeks of treatment," said Laurent Peyrin-Biroulet, MD PhD, Professor of Medicine and Head of the Inflammatory Bowel Disease Unit, Inserm, University Hospital of Nancy, France. "These results continue to support etrasimod's potential as an important future therapy and we look forward to further validating these data in the soon to be initiated ELEVATE Phase 3 clinical program for etrasimod in UC."

Etrasimod Presentation Details - Awarded "Top-10 Oral Poster Presentation"
Title: Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis

"Non-opioid-based treatments for visceral pain associated with Crohn's disease address an area of significant unmet need, especially in patients in whom nonsteroidals and opioids are restricted," stated Peter Doyle Higgins MD, PhD, Professor, Director of Inflammatory Bowel Disease Program, Director of Ambulatory and Chronic Disease Clinical Trials Support Unit, University of Michigan. "These data from the olorinab program highlight its potential as a novel approach for the management of GI pain that may lack abuse potential. I look forward to further clinical studies of this promising candidate therapy in Crohn's disease and IBS with the hopes of providing a new treatment option to patients in need of relief from chronic abdominal pain."

Olorinab Presentation Details
Title: Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly-Selective, Cannabinoid Receptor 2 Agonist in a Phase 2a Study in Chronic Abdominal Pain Associated with Crohn's Disease

About Etrasimod
Etrasimod (APD334), is a next generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator, discovered by Arena, designed to provide systemic and local cell modulation by selectively targeting S1P receptor subtypes 1, 4 and 5. Etrasimod has therapeutic potential in immune and inflammatory-mediated diseases such as ulcerative colitis, Crohn's disease, and atopic dermatitis. S1P receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage.

Etrasimod is an investigational compound that is not approved for any use in any country.

About Olorinab
Olorinab (APD371) is an oral, peripherally restricted, highly selective, full agonist of cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, including Crohn's disease and irritable bowel syndrome (IBS). Evidence that CB2 are expressed in multiple cell types of the GI tract, and modulate intestinal inflammation and visceral hypersensitivity, make CB2 an attractive target for the treatment of abdominal pain in GI disorders.

Olorinab is an investigational compound that is not approved for any use in any country.

About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease, as well as in programs for other indications such as atopic dermatitis. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure. Arena's licensee, United Therapeutics, is evaluating ralinepag in a Phase 3 program for pulmonary arterial hypertension (PAH).

Arena has additional license agreements and partnerships, including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "potential," "future," "look forward to," "soon to be," "may," "promising," "hopes of," "designed to," "in development for," "driven to," "potentially," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the following: the opportunity, development and potential of etrasimod, olorinab and Arena's other investigational drug candidates, including to be first- or best-in-class, have broad clinical utility, lack abuse potential, or satisfy an unmet medical need; Arena's drive; and the potential of Arena's assets, programs, licenses, and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include: the timing and outcome of research, development and regulatory review is uncertain; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; nonclinical and clinical data are voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; we expect to need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; clinical trials and other studies may not proceed at the time or in the manner expected or at all; enrolling patients in our ongoing and intended clinical trials is competitive and challenging; our drug candidates may not advance in development or be approved for marketing; unexpected or unfavorable new data; risks related to developing and commercializing drugs; risks related to relying on partners and other third parties; Arena's and third parties' intellectual property rights; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 28, 2019. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636

Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384

https://mma.prnewswire.com/media/436843/Arena_Pharmaceuticals_Logo.jpg


https://c212.net/c/img/favicon.png?sn=LA77356&sd=2019-03-08 View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-phase-2-data-for-etrasimod-and-olorinab-at-the-14th-congress-of-european-crohns-and-colitis-organisation-300808996.html

SOURCE Arena Pharmaceuticals, Inc.

Arena all set to ring the Opening Bell on the Nasdaq tomorrow

Great earnings beat and CC. Interested to see what happens here

The reverse split happened in June of 2017, so at this point we can say that it did work out fine.

Thanks MM. An R/S usually don't work. REN did an R/S and it worked out bigly for me. Maybe ARNA will too but I can't jump in at this stage. Wish you good luck.

Feb 27 Presentation at Leerink Global Healthcare Conference

https://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-on-february-27-300799306.html

The Mergers And Acquisitions Theme, article by CFA holder

https://seekingalpha.com/article/4240702-biotech-bonanza-mergers-acquisitions-theme

"A few promising biotech companies, some of which may be now or in the past part of the Prudent Biotech model portfolios, include... Arena Pharmaceuticals (ARNA),..."

Yes r/s...1 for 10 I believe. So it's $4.80 in years ago dollars

Hi. I was watching ARNA a few years back before it popped to 13 and then had the long decent to $1. I looked again and it's now trading in the big boy range. Can someone give me the quick story here? Was it an RS or did it really climb that far?

Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress

SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal diseases, at the Crohn's & Colitis Congress® in Las Vegas, NV.

Presentation Details:
Title: Olorinab, a Peripherally Restricted, Highly Selective Agonist of the Cannabinoid Receptor Type 2 for the Management of Visceral Pain in Inflammatory Bowel Disease (IBD)—Preclinical and Early Clinical Development
Poster Presentation Dates: Thursday, Feb. 7, 7:15PM PST and Friday, Feb. 8, 3:50PM PST

About Olorinab
Olorinab (APD371) is an oral, peripherally restricted, highly selective, full agonist of cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, including Crohn's disease and irritable bowel syndrome (IBS). Evidence that CB2 are expressed in multiple cell types of the GI tract, and modulate intestinal inflammation and visceral hypersensitivity, make CB2 an attractive target for the treatment of abdominal pain in GI disorders.

Olorinab is an investigational compound that is not approved for any use in any country.

About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease, as well as in programs for other indications such as atopic dermatitis. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure. Arena's licensee, United Therapeutics, is evaluating ralinepag (APD811) in a Phase 3 program for pulmonary arterial hypertension (PAH).

Arena has additional license agreements and partnerships, including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "will," "in development for," "driven to," "potentially," "potential," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the following: the opportunity, development and potential of olorinab and Arena's other investigational drug candidates, including to be first- or best-in-class, have broad clinical utility, or have utility in a broad range of immune and inflammatory conditions; Arena's drive; and the potential of Arena's assets, programs, licenses, and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include: the timing and outcome of research, development and regulatory review is uncertain; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; nonclinical and clinical data are voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; we expect to need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; clinical trials and other studies may not proceed at the time or in the manner expected or at all; enrolling patients in our ongoing and intended clinical trials is competitive and challenging; our drug candidates may not advance in development or be approved for marketing; unexpected or unfavorable new data; risks related to developing and commercializing drugs; risks related to relying on partners and other third parties; Arena's and third parties' intellectual property rights; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which was filed with the SEC on November 8, 2018. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636

Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384

https://mma.prnewswire.com/media/436843/Arena_Pharmaceuticals_Logo.jpg


https://c212.net/c/img/favicon.png?sn=LA47919&sd=2019-02-07 View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presents-preclinical-and-early-clinical-development-data-for-olorinab-at-crohns--colitis-congress-300792077.html

SOURCE Arena Pharmaceuticals, Inc.

Is this stock starting to pop?

Wind in the sails as media positive on biotech in 2019

https://www.cnbc.com/2019/01/08/biotech-break-out-why-some-market-experts-see-an-even-bigger-rally.html

https://www.cantechletter.com/2019/01/investors-can-find-defensive-plays-in-biotech-eden-rahim-says/

https://247wallst.com/healthcare-business/2019/01/02/why-value-investors-may-flock-to-top-biotechs-in-2019/

https://www.cnbc.com/2019/01/02/the-best-performing-sector-last-year-could-be-the-top-bet-for-2019.html

PPS approaching upper band from mid June 2018

...as CEO presentation due today. it probably needs to cross about 45.50 for a breakout. It already hit 44.99 before any news.

So - it's been about 35 days since the Ralinepag deal was announced. HSR Act wait time is normally 30 days, right? We hear nothing from either company. ARNA stock trading like the deal is not happening. i.e., we're now trading way lower than the day the deal was announced. Anyone have any scoop? I did drop a note to IR @ arena. Not surprisingly - no response. Gotta love the market these days.

CEO Corporate Update on Jan 10 at JP Morgan conference

https://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-on-january-10-300768611.html

Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry.

"Manmeet brings deep financial and business expertise to the board, and we are thrilled to welcome him," said Tina Nova, Chairman of the Board of Directors of Arena. "His leadership abilities and senior finance experience within the life sciences industry will be instrumental as we strategically advance Arena towards its next stage of growth."

Mr. Soni has served as Senior Vice President, Chief Financial Officer of Alnylam Pharmaceuticals, Inc. since May 2017. From March 2016 to February 2017, he was Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Previously, Mr. Soni served as Chief Financial Officer of Pharmacyclics, Inc., a publicly-held biopharmaceutical company, until its acquisition by AbbVie, Inc. in May 2015. He first joined Pharmacyclics in September 2012 as corporate controller and served in various increasingly senior roles prior to being appointed Chief Financial Officer and Treasurer in February 2014. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly held medical technology company, as well as PricewaterhouseCoopers, in the Life Science and Venture Capital Group and PricewaterhouseCoopers India, providing audit and assurance services. Mr. Soni currently serves as director of Pulse Biosciences, Inc. He is a certified public accountant and completed his Chartered Accountancy from the Institute of Chartered Accountants of India.

About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease, as well as in programs for primary biliary cholangitis (PBC) and atopic dermatitis. Ralinepag (APD811) is being evaluated in a Phase 3 program for pulmonary arterial hypertension (PAH). Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.

In addition, Arena has several partnerships including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "will," "driven to," "potentially," "potential," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about Mr. Soni's expected contribution; Arena's potential strategic advancement toward its next stage of growth; and Arena's drive, focus, goals, strategy, clinical and research and development programs, and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include the timing and outcome of research, development and regulatory review is uncertain; clinical programs may not proceed at the time or in the manner expected or at all; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; and other risks related to developing and commercializing drugs; as well as those factors disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which was filed with the SEC on November 8, 2018. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636

Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384

https://mma.prnewswire.com/media/436843/Arena_Pharmaceuticals_Logo.jpg


https://c212.net/c/img/favicon.png?sn=LA03220&sd=2018-12-17 View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-appoints-experienced-life-sciences-industry-finance-executive-manmeet-s-soni-to-board-of-directors-300765983.html

SOURCE Arena Pharmaceuticals, Inc.

Feb 2018 support for hypothesis: Novartis & Arena

"Rivals may profit off Celgene’s pain. Novartis AG (ADR)'s Gilenya and Arena Pharmaceuticals, Inc.’s etrasimod were expected to cede market share to ozanimod — a threat that weighed on the developers’ theses."

https://www.benzinga.com/general/biotech/18/02/11275518/regulatory-concern-for-celgenes-ozanimod-could-be-big-for-arena-pharm

Novartis could take control of this market with an acquisition of Arena (through selling stake in Roche) if they believe Etrasimod would otherwise threaten Gilenya.

Background:
https://www.specialtypharmacytimes.com/news/fda-stopping-ms-treatment-gilenya-may-lead-to-severe-disease-worsening

https://www.fool.com/investing/2018/02/14/celgenes-future-growth-could-depend-on-a-competito.aspx

https://www.medpagetoday.com/meetingcoverage/acg/75588

Speculation only: who could be a potential buyer of Arena?

https://www.breakingthenews.net/fitch-cuts-novartis-to-aa-for-acquisitive-strategy/news/details/45800816

"We believe that Novartis could use its non-strategic 6.3% stake in its competitor Roche to finance larger acquisitions to protect its financial risk profile..."

Swiss Franc is still strong but that could change with rising interest rates.

Arena Pharmaceuticals management to meet with Leerink: Dec 12, Zuerich

https://thefly.com/landingPageNews.php?id=2835081&headline=ARNA-Arena-Pharmaceuticals-management-to-meet-with-Leerink

I hope that CEO Amit Munshi has a chance to showcase Arena in the presence of representatives of BP companies, such as Joseph J. Wolk, Executive Vice President and Chief Financial Officer Johnson & Johnson, at the Citi global healthcare conference today in New York.

I agree with you. ARNA was held back at the equivalent of USD135 per share immediately after the FDA decision on Belviq. That must have been an enormous undertaking given the momentum for the first obesity drug ever approved. The changes in price and relentless drop over years wore most retail out. The change in attitude in the media is clear with blame placed on past management this month.

The Bloomberg article on $ARNA illustrated nicely just how incredibly overvalued that stock is today.— Adam Feuerstein ✡️ (@adamfeuerstein) July 9, 2012
$ARNA pipeline is legit. You’re remembering the past correctly, but different company today.— Adam Feuerstein ✡️ (@adamfeuerstein) November 15, 2018

At the same time, the stock has been carefully labelled "speculative". That is like waving a red flag to a bull. The bull will come soon enough.

https://seekingalpha.com/article/4222767-arena-pharmaceuticals-speculative-cramers-lightning-round-11-15-18

Short % has been dropping over the month
https://fintel.io/ss/us/arna

don't know what happened there around 2:30 Wed afternoon. Was very strange. All day long (until the reversal @ 2:30) I thought the MM was gonna try to keep it down around 39 - max pain point for the friday options... well - nope that's not it, cuz he then let it run @ 2:30 PM. Who knows what Friday will bring.

I do believe there is a lot of intra-day shorting going on, and to me the intent really appears to be just to take the steam out of any rallies. And I wish FINRA would report ALL activity. I have yet to fully understand why FINRA-reported volume is usually way less than half of true volume. Why give us any info on short activity if you can't give us the COMPLETE picture, FINRA? Can't make informed decisions based on flawed stats. Am rambling.

Anyway, with the intra-day shorting to stifle rallies, combined with the large block trades every day @ the CLOSE (and at the closing price), I'm still of the mind that somebody big is accumulating. Maybe once whoever that is is satisfied with their position(and FMR is done selling), ARNA will finally be allowed to run. I do believe it is horribly undervalued here around $40, and some entity is working hard to keep us undervalued. For now.